News

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

Intensity Therapeutics Recognizes Rare Disease Day 2019

Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors

Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences

Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO conference.

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences

Intensity Therapeutics Issued New Patents for Technology Platform

Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial

Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models

Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6

Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation

Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6